Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ambarella surges after report says company exploring strategic options, including sale (SeekingAlpha) +++ AMBARELLA Aktie +15,53%

CITIUS PHARMACEUTICALS Aktie

>CITIUS PHARMA Performance
1 Woche: 0%
1 Monat: 0%
3 Monate: 0%
6 Monate: 0%
1 Jahr: 0%
laufendes Jahr: 0%
>CITIUS PHARMACEUTICALS Aktie
Name:  CITIUS PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US17322U3068 / A40MD0
Symbol/ Ticker:  47N0 (Frankfurt) / CTXR (NASDAQ)
Kürzel:  FRA:47N0, ETR:47N0, 47N0:GR, NASDAQ:CTXR
Index:  -
Webseite:  https://www.citiuspharma...
Marktkapitalisierung:  -
Umsatz:  -
EBITDA:  -
Gewinn je Aktie:  -
Schulden:  -
Liquide Mittel:  -
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / - / -
Gewinnm./ Eigenkapitalr.:  - / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  CITIUS PHARMACEUTICALS, CITIUS PHARMA, CITIUS PHARMACEUTICAL
Letzte Datenerhebung:  24.06.25
>Eigentümer
Aktien: -
f.h. Aktien: -
Insider Eigner: -
Instit. Eigner: -
>Peer Group

 
17.06.25 - 14:09
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 (PR Newswire)
 
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an......
12.06.25 - 14:36
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
 
$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J., June 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical......
10.06.25 - 13:45
Citius Pharmaceuticals announces registered direct offering of $15.8 million (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.06.25 - 13:09
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
 
$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J., June 10, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical......
09.06.25 - 15:42
Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR (AFX)
 
WASHINGTON (dpa-AFX) - Citius Oncology, Inc. (CTOR), the oncology-focused subsidiary of late-stage biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR), announced Monday it has entered in......
09.06.25 - 14:39
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire)
 
Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")......
14.05.25 - 23:00
Citius Pharmaceuticals GAAP EPS of -$0.11 beats by $0.27 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.05.25 - 22:33
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
 
CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial......
05.05.25 - 14:39
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (PR Newswire)
 
CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur, Chairman and Chief Executive......
01.04.25 - 15:15
Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.03.25 - 22:33
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight (PR Newswire)
 
With the emergence of novel therapies and expanded indications, the United States IL-2 market is projected to reach USD 4 billion by 2034. Key players driving this expansion include Iovance Biotherapeutics, Eisai, Citius Pharmaceuticals, Nektar Therapeutics, Mural Oncology, Corvus......
26.11.24 - 08:03
XFRA : INSTRUMENT_SUSPENSION - US17322U3068 (XETRA)
 
Instrument ID [21765584] (47N0 - US17322U3068) suspended...
26.11.24 - 08:03
XFRA : 47N0: Aussetzung/Suspension (XETRA)
 
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CITIUS PHARMAC. DL -,001 47N0 US17322U3068 BAW/UFN...
25.11.24 - 23:57
XFRA : NEW INSTRUMENT AVAILABLE - 26.11.2024 - US17322U3068 (XETRA)
 
Das Instrument 47N0 US17322U3068 CITIUS PHARMAC. DL -,001 EQUITY hat seinen ersten Handelstag am 26.11.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument 47N0 US17322U3068 CITIUS PHARMAC. DL -,001 EQUITY has its first trading date on 26.11.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
25.11.24 - 16:52
XFRA : ISIN Change (XETRA)
 
Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US15130G8087 Cemtrex Inc. 25.11.2024 US15130G8814 Cemtrex Inc. 26.11.2024 Tausch 35:1 SE0008212161 Svenska Aerogel Holding AB 25.11.2024 SE0023440557 Svenska Aerogel Holding AB 26.11.2024 Tausch 100:1 CA53044R2063 Liberty Defense Holding Ltd. 25.11.2024 CA53044R8839 Liberty Defense Holdings Ltd. 26.11.2024 Tausch 10:1 US17322U2078 Citius Pharmaceuticals Inc. 25.11.2024 US17322U3068 Citius Pharmaceuticals Inc. 26.11.2024 Tausch 25:1 LU2391723694 Perimeter Solutions S.A. 25.11.2024 US71385M1071 Perimeter Solutions Inc. 26.11.2024 Tausch 1:1...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!